Scholarlink

Abstract <p>Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist,is widely used now for the treatment of type 2 diabetes (T2D) andobesity. However, its effects on endocrine functions compromisedin these conditions remain poorly understood. Moreover, there areno data on the potential enhancement of Semaglutide effects in thepresence of intranasal insulin (INI). This study was aimed to investigatethe influence of a four-week treatment of mature male rats withT2D using Semaglutide (50 µg/kg/day, s.c.) and its combination withINI (2 IU/rat/day) on hormonal parameters of the thyroid and gonadalsystems. T2D was induced by a high-fat diet and a low-dose streptozotocin. Alongwith glucose homeostasis parameters and insulin levels, the bloodlevels of thyroid hormones (fT4, tT4, fT3, tT3), thyroid-stimulatinghormone (TSH), testosterone, and luteinizing hormone (LH) were assessed.In T2D rats, Semaglutide reduced body weight and fat mass, improvedglucose tolerance and insulin sensitivity, restored triiodothyroninelevels and peripheral conversion of thyroid hormones. Semaglutideand INI co-application enhanced the stimulatory effects of the formeron thyroid hormone levels reduced in T2D, and normalized TSH levels(elevated in T2M) and thyroid gland sensitivity to TSH, as assessedby the integral thyroid index. Both Semaglutide monotherapy andits combination with INI partially restored testosterone levelsreduced in T2D, preventing androgen deficiency. Thus, Semaglutideand its combination with INI can be used to correct endocrine disordersin T2D, which is important for clinical endocrinology and reproductivemedicine.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of Four-Week Semaglutide Therapy and Its Combination with Intranasal Insulin on Thyroid and Gonadal Status in Male Rats with Type 2 Diabetes

  • 期刊论文

  • 发表日期：

    2025年5月1日

查看全文
  • K. V. Derkach,
  • I. I. Zorina,
  • I. V. Fedorchuk,
  • A. O. Shpakov

摘要

Abstract

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist,is widely used now for the treatment of type 2 diabetes (T2D) andobesity. However, its effects on endocrine functions compromisedin these conditions remain poorly understood. Moreover, there areno data on the potential enhancement of Semaglutide effects in thepresence of intranasal insulin (INI). This study was aimed to investigatethe influence of a four-week treatment of mature male rats withT2D using Semaglutide (50 µg/kg/day, s.c.) and its combination withINI (2 IU/rat/day) on hormonal parameters of the thyroid and gonadalsystems. T2D was induced by a high-fat diet and a low-dose streptozotocin. Alongwith glucose homeostasis parameters and insulin levels, the bloodlevels of thyroid hormones (fT4, tT4, fT3, tT3), thyroid-stimulatinghormone (TSH), testosterone, and luteinizing hormone (LH) were assessed.In T2D rats, Semaglutide reduced body weight and fat mass, improvedglucose tolerance and insulin sensitivity, restored triiodothyroninelevels and peripheral conversion of thyroid hormones. Semaglutideand INI co-application enhanced the stimulatory effects of the formeron thyroid hormone levels reduced in T2D, and normalized TSH levels(elevated in T2M) and thyroid gland sensitivity to TSH, as assessedby the integral thyroid index. Both Semaglutide monotherapy andits combination with INI partially restored testosterone levelsreduced in T2D, preventing androgen deficiency. Thus, Semaglutideand its combination with INI can be used to correct endocrine disordersin T2D, which is important for clinical endocrinology and reproductivemedicine.